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Abstract
Background: Chronic hepatitis C (HCV) disease can be complicated with comorbid conditions that may impact
treatment eligibility and outcomes. The aim of the study was to systematically review comorbidities and symptoms
in an HCV infected population, specifically assessing comorbidities associated with HCV anti-viral treatment and
disease, as well as comparing comorbidities between an HCV infected and uninfected control population.
Methods: This was a retrospective cohort study within a United States medical claims database among patients
with chronic HCV designed to estimate the two-year period prevalence of comorbidities. Patients with two HCV
diagnosis codes, 24 months of continuous health insurance coverage, and full medical and pharmacy benefits
were included.
Results: Among a chronic HCV cohort of 7411 patients, at least one comorbid condition was seen in almost all
patients (> 99%) during the study period. HCV-infected patients reported almost double the number of
comorbidities compared to uninfected controls. Of the 25 most common comorbidities, the majority of the
comorbidities (n = 22) were known to be associated with either HCV antiviral treatment or disease. The five most
frequent comorbidities were liver disease [other] (37.5%), connective tissue disease (37.5%), abdominal pain (36.1%),
upper respiratory infections (35.6%), and lower respiratory disease (33.7%). Three notable comorbidities not known
to be associated with antiviral treatment or disease were benign neoplasms (24.3%), genitourinary symptoms & ill-
defined conditions (14.8%), and viral infections (13.8%).
Conclusions: This US medically insured HCV population is highly comorbid. Effective strategies to manage these
comorbidities are necessary to allow wider access to HCV treatment and reduce the future burden of HCV disease
and its manifestations.
Background
Hepatitis C virus (HCV) is the etiology of the most
common chronic bloodborne infection in the United
States (US), affecting at least 4.1 million people, of
whom 3.2 million are chronically infected [1]. Chronic
infection can lead to progressive development of liver
fibrosis to cirrhosis, end-stage liver disease, and hepato-
cellular carcinoma (HCC) in 5-20% of patients within
the first two decades of initial infection [2]. Complica-
tions of chronic HCV are projected to increase dramati-
cally over the next few decades [3], placing an ever
greater burden on health systems of a disease where the
annual health care costs are already estimated at over
one billion dollars [4]. Known co-factors for the pro-
gression of liver disease include duration of infection,
male gender, high-levels of alcohol consumption, hepati-
tis B virus (HBV) infection, and human immunodefi-
ciency virus (HIV) infection. Other data show that
metabolic factors such as steatosis, being overweight or
obese may also contribute to progression [5]. Several of
these factors are comorbid conditions that may also
impact HCV treatment eligibility and outcomes. Other
conditions that are known contraindications for HCV
treatment are severe depressive disorders, hyperthyroid-
ism, hypertension, heart failure, coronary heart disease,
diabetes, and pulmonary disease [2].
The current standard-of-care for chronic HCV treatment
is combination pegylated-interferon and ribavirin with the
addition of boceprevir or teleprevir for genotype 1 patients
only [6]. Among patients on pegylated-interferon and
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mately 55% of treatment-naïve patients [7]. About 75% of
treated patients experience one or more side effects requir-
ing discontinuation or dose modification of treatment [8].
Specifically, antiviral treatment may exacerbate certain con-
ditions such as those with anaemia, thrombocytopenia or
leukopenia, which can further complicate treatment out-
comes by increasing the number and severity of side-effects
[9]. Consequently, many patients are excluded from treat-
ment, or have treatment deferred or compromised because
of their comorbid conditions.
To maximize the benefit of current and future HCV
therapeutic regimens, a greater understanding of the
most frequent comorbidities associated with HCV is
needed. Successfully managing these comorbidities may
lead to increased treatment eligibility and improved out-
comes. No studies, to our knowledge have systematically
profiled comorbidities among a general HCV population.
The objectives of this study were: (1) to systematically
estimate the prevalence of the top 25 comorbidities in an
HCV population; (2) to compare whether these most
common HCV comorbidities differ between receiving
antiviral treatment during the study period; and (3) to
compare whether these most common HCV comorbid-
ities differ between an HCV infected and uninfected con-
trol population.
Methods
Study population
Our study population was individuals within the Inte-
grated Health Care Information System (IHCIS) National
Benchmark database. IHCIS is a US medical claims data-
base that holds claims and patient diagnosis information
from over 30 health care plans in 8 census regions. Sub-
jects for our study came from IHCIS covering claims from
November 1998 to May 2006. At the time of analyses,
approximately 41 million people (14%) have contributed
to the database. Over 90% of patients belonging to IHCIS
have medical benefits, and approximately 84% also have
pharmacy benefits. The IHCIS database is de-identified
and is compliant to the Health Insurance Portability and
Accountability Act (HIPAA) for disclosure of protected
health information.
Disease classification systems
HCV, HCV disease severity, and comorbidities (compris-
ing both conditions and symptoms) were initially identi-
fied using the International Classification of Disease
version 9 (ICD-9 codes) in IHCIS, and then further classi-
fied according to the Clinical Classifications Software
(CCS) 2006 tool from the U.S. Agency for Healthcare
Research and Quality [9]. The tool categorizes 12,000
ICD-9 codes into a manageable number of clinically
meaningful categories to aid understanding patterns of
diagnoses associated with particular illnesses. CCS has a
single-level system that categorizes diagnoses into
mutually exclusive categories, and a multi-level hierarchi-
cal system that expands the single-level categories into
broader categories that provide more detail about the
grouping of diagnoses; we used the latter to define comor-
bidities. When possible, common comorbidities were iden-
tified at the third CCS multi-level classification. However,
some conditions with second level categories did not dif-
ferentiate into a third-level and were reported at the sec-
ond level; likewise, if first-level categories did not
differentiate into a second-level, they were reported at the
first-level. In addition, drug use (ICD-9 292.xx, 304.xx,
305.xx [except 305.00, 305.01-305.03], and alcohol use
(291.xx, 303.xx, 305.0, 305.01-305.03, 790.3, 980.0, 980.8,
980.9, 571.x, 535.3, 357.5, 425.5, E860.0, E860.1, E860.8,
E860.9) [6] were identified by ICD-9 codes since they were
not defined by the CCS classification system. Multiple
claims of a comorbidity were counted only once. We
excluded comorbidities reflecting acute conditions, inju-
ries/poisoning, gender-related conditions, and routine/
health maintenance (Refer to Additional file 1). In order to
provide greater specificity of the conditions defined within
each CCS category, we cross-tabulated CCS codes with
ICD-9 codes for the top 25 ranked CCS codes.
Following the convention of Feinstein [10], the term
comorbidity refers to any distinct clinical entity that has
existed or that may occur during the course of HCV
disease. As such, these are not limited to those that are
associated with HCV disease/treatment. Comorbidities
associated with HCV antiviral treatment and comorbid-
ities that exclude patients from initiating treatment were
identified according to AASLD (American Association
for the Study of Liver Diseases), CDC (Centers for Dis-
ease and Control and Prevention), and NIH (National
Institute of Health) management practice guidelines (see
Table 1).
Case and control definitions
Cases were HCV patients defined as treated or untreated.
Untreated cases had at least two ICD-9 diagnosis codes
for chronic HCV (070.41, 070.44, 070.51, 070.54, 070.70,
070.71, 070.7, V0.262) and no a-interferon claims record,
with the second code occurring 6-12 months after the
first code. The second ICD-9 code was used to confirm
the HCV diagnosis and its date is referred to as the HCV
index date. Treated cases had at least one a-interferon
claim after their first HCV ICD-9 code. If the date of the
first interferon claim occurred within 6-12 months after
the first HCV diagnosis code and before a second chronic
HCV ICD-9 code, it was considered the index date. We
were unable to capture HCV diagnoses or treatments
that may have been received prior to patient enrollment
in IHCIS.
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no other HCV codes were excluded from analyses. For
study eligibility, subjects also had to have at least 24
months of follow-up in IHCIS (12 months pre- and 12
months post- the HCV index date), no gaps in health
coverage, and full medical and pharmacy benefits
coverage.
Controls were enrollees without HCV who were ran-
domly selected from ICHIS, and were matched to a case
(1:1) on age (within 1 year), sex, continuous medical health
coverage, and enrollment period. The study period during
which comorbidities were identified was the 12 months
pre- and 12 months post- HCV index date. Patient age
was calculated at the index date.
Disease severity
Initially, disease severity was classified into four cate-
gories: no cirrhosis, cirrhosis (ICD-9: 571.2, 571.5, 571.6,
572.2, 572.3, 572.4), hepatocellular carcinoma (HCC;
ICD-9: 155.0, 155.1, 155.2, 230.8, V10.07), and end-stage
liver disease (ICD-9: 070.44, 070.41). However, no
patients were identified with end-stage liver disease and
127 were diagnosed with HCC. Given the small number
of patients with HCC, we grouped HCC patients with
cirrhotic patients, and they were referred to as those
with ‘advanced liver disease’.
Statistical analysis
The period prevalence of comorbidities during the 24-
month study period was calculated. To compare the
prevalence of comorbidities by treatment status for
HCV patients, prevalence odds ratios (OR), 95% confi-
dence intervals (CI), and p-values were calculated using
logistic regression models, and were adjusted for age,
sex, and advanced liver disease status. When comparing
comorbidities in the HCV population to the matched
uninfected control population, hazard ratios and 95% CI
were calculated using conditional logistic regression. All
analyses were performed using SAS statistical package
(SAS Institute Inc, Cary, NC, Version 9.1).
Results
HCV study population characteristics
A total of 7411 chronic HCV patients were included in
this analysis (Table 2). The study population was predo-
minantly male (62.9%) and the median age was 49 years.
Almost half of the patients received interferon during
the study period (46.8%) and 19.7% had advanced liver
disease. Most patients were from the northeast region of
the United States (63.8%) and 83.1% of patients had
HMO (health maintenance organization) or PPO (pre-
ferred provider organization) insurance. When compar-
ing HCV infected cases vs. HCV uninfected controls,
reported drug use (14.9% vs. 3.2%) and alcohol use
(6.5% vs. 0.85%) was much higher among cases. Also,
both drug use and alcohol use were 1.3- and 1.7- fold
higher among HCV untreated patients versus the treated
population.
Overall frequency of HCV comorbidities
Comorbidities were common in this insured HCV popu-
lation (Figure 1). Almost all HCV patients (99.4%)
Table 1 Conditions associated with HCV treatment and disease
Conditions associated with treatment
Conditions associated with Interferon alfa
or Ribavirin use [2]
(see Table 3; denoted by A)
Interferon only:
neutropenia, thrombocytopenia, depression, hypothyroidism and hyperthyroidism, irritability,
concentration and memory disturbances, visual disturbances, muscle aches, headaches, nausea and
vomiting, low-grade fever, weight loss, insomnia, hearing loss and tinnitus, interstitial fibrosis and hair
thinning
Both Interferon and Ribavirin:
skin irritation, fatigue
Ribavirin only:
hemolytic anemia, birth defects and gout
Concurrent disease for which therapy is
contraindicated [2]
(See Table 3; denoted by B)
major uncontrolled depressive illness; solid organ transplant (renal, heart, or lung); autoimmune
hepatitis or other autoimmune condition known to be exacerbated by peginterferon and ribavirin,
untreated thyroid disease; severe concurrent medical disease such as severe hypertension, heart failure,
significant coronary heart disease, poorly controlled diabetes and chronic obstructive pulmonary
disease
Conditions associated with disease
Symptoms of HCV disease [11]
(see Table 3; denoted by C)
fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel
movements, joint pain and jaundice
Extrahepatic manifestations associated with
HCV infection [12]
(see Table 3; denoted by D)
rheumatoid symptoms, keratoconjunctivitis sicca, lichen planus, glomerulonephritis, lymphoma,
porphyria cutanea tarda, psychological disorders and essential mixed cryoglobulinemia
Conditions associated with disease
progression [2,13]
(see Table 3; denoted by E)
alcohol use, HIV, HBV and obesity essential hypertension [12] (evidence of reducing HCV disease
progression)
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reported none. Fifteen percent reported ≤5 comorbidities,
whereas 52% reported 6-15 comorbidities, and 5.5%
reported ≥31 conditions. When comparing HCV-infected
patients to uninfected controls, HCV-infected patients
reported almost double the number of comorbidities
(101,219 vs. 53,589, respectively). More uninfected con-
trol patients (37.4%) reported ≤5 comorbidities compared
to case patients (14.8%). The HCV infected population
w a sm o r el i k e l yt or e p o r t≥21 comorbidities than the
uninfected, 13.5% vs. 3.7%, respectively.
Top 25 most common comorbidities
T a b l e3p r e s e n t sar a n k e dl i s to ft h et o p2 5m o s tc o m -
mon comorbidities in the overall HCV population, and
also presents the frequency of these conditions among
the treated and untreated HCV populations. In addition,
the association (odds ratios adjusted for age, sex, and
advanced liver disease) of the comorbidity between
HCV treated and untreated, and between the HCV-
infected (all) compared to the uninfected controls are
Table 2 Characteristics of HCV study population
Received HCV treatment during study period
Total (n = 7411) Yes (n = 3469) No (n = 3942)
n% n % n %
Gender
Female 2750 37.1 1134 32.7 1616 41.0
Male 4661 62.9 2335 67.3 2326 59.0
Age category
0-19 18 0.2 3 0.1 15 0.4
10-19 51 0.7 18 0.5 33 0.8
20-29 142 1.9 55 1.6 87 2.2
30-39 716 9.7 342 9.9 374 9.5
40-49 3194 43.1 1583 45.6 1611 40.9
50-59 2714 36.6 1294 37.3 1420 36.0
60-64 329 4.4 137 3.9 192 4.9
65+ 247 3.3 37 1.1 210 5.3
Census Region
Midwest 305 4.1 142 4.1 163 4.1
Northeast 4730 63.8 2259 65.1 2471 62.7
South 700 9.4 368 10.6 332 8.4
West 369 5.0 134 3.9 235 6.0
Other
a 1307 17.6 566 16.3 741 18.8
Health insurance type
b
Health Maintainance Organization 3247 43.8 1500 43.2 1747 44.3
Individual Plans 302 4.1 142 4.1 16. 4.1
Point of Service 755 10.2 382 11.0 373 9.5
Preferred Provider Organization 2914 39.3 1405 40.5 1509 38.3
Other 167 2.3 39 1.1 128 3.2
Advanced liver disease 1462 19.7 1017 29.3 445 11.3
Cirrhosis 1335 18.0 926 26.7 409 10.4
Hepatocellular carcinoma 127 1.7 91 2.6 36 0.9
Drug use 1101 14.9 447 12.9 654 16.6
Alcohol use 485 6.5 166 4.8 319 8.1
a Other region includes other regions and regions which were masked for confidentiality purposes
b 26 patients had unknown health insurance type.
Figure 1 The proportion of HCV infected cases and HCV
uninfected controls reporting comorbidities.
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Page 4 of 11Table 3 25 most prevalent comorbidities and symptoms in the overall HCV population stratified and compared by antiviral treatment status and control
patients without HCV
Prevalence
Rank Comorbidity CCS
code
Comorbidities
associated with
HCV treatment
and disease‡
No. of total
HCV cases (n
= 7411)
% No. of HCV
treated patients
(n = 3469)
% No. of HCV
untreated
patients (n =
3942)
% No. of HCV
uninfected
controls (n =
7411)
% Odds ratio (95%
CI): treated vs
untreated *
Odds ratio (95%
CI): HCV cases vs.
controls
1 Liver disease, other
a 9.8.2 C 2779 37.5 1451 41.8 1328 33.7 221 3.0 1.34 (1.21-1.47) 19.67 (16.57-23.36)
2 Connective tissue
disease, other
b
13.8 A, D 2776 37.5 1200 34.6 1576 40.0 2050 27.7 0.81 (0.74-0.90) 1.59 (1.48-1.70)
3 Abdominal pain 17.1.7 C 2675 36.1 1212 34.9 1463 37.1 1029 13.9 0.90 (0.81-0.99) 3.55 (3.25-3.87)
4 Upper respiratory
disease, and other
8.1.5 A 2640 35.6 1204 34.7 1436 36.4 2194 29.6 0.96 (0.87-1.05) 1.33 (1.24-1.43)
5 Lower respiratory
disease, and other
unspecified
c
8.8.3 B° 2494 33.7 1197 34.5 1297 32.9 1332 18.0 1.06(0.96-1.17) 2.39 (2.21-2.59)
6 Essential
hypertension
7.1.1 E 2416 32.6 1099 31.7 1317 33.4 1914 25.8 0.93 (0.84-1.03) 1.42 (1.32-1.53)
7 Back problems, and
other
d
13.3.3 C 2409 32.5 1046 30.2 13.63 34.6 1502 20.3 0.84 (0.76-0.92) 1.90 (1.76-2.05)
8 Non-traumatic joint
disorders, other
e
13.2.3 C 2172 29.3 877 25.3 1295 32.9 1484 20.0 0.71 (0.64-0.78) 1.66 (1.53-1.79)
9 Skin disorders, other
f 12.4 A 2125 28.7 998 28.8 1127 28.6 1649 22.3 1.06 (0.95-1.17) 1.40 (1.30-1.51)
10 Nonspecific chest
pain
7.2.5 A, C 1960 26.5 859 24.8 1101 27.9 1154 15.6 0.84 (0.76-0.94) 1.98 (1.82-2.15)
11 Disorders of lipid
metabolism
3.6 C 1920 25.9 813 23.4 1107 28.1 2384 32.2 0.80 (0.72-0.89) 0.73 (0.68-0.79)
12 Malaise and fatigue 17.1.8 A 1887 25.5 933 26.9 954 24.2 866 11.7 1.18 (1.07-1.32) 2.62 (2.39-2.87)
13 Gastrointestinal
disorders, other and
unspecified
g
9.12.3 C 1807 24.4 836 24.1 971 24.6 708 9.6 0.93 (0.84-1.04) 3.11 (2.81-3.43)
14 Benign neoplasm,
other and
unspecified
h
2.16.2 Unk 1798 24.3 833 24.0 965 24.5 1333 18.0 1.00 (0.90-1.12) 1.48 (1.36-1.61)
15 Anemia deficiency,
other
4.1.3 A 1648 22.2 983 28.3 665 16.9 441 6.0 1.99 (1.77-2.23) 4.57 (4.06-5.14)
16 Esophageal
disorders
i
9.4.1 E 1518 20.5 674 19.4 844 21.4 709 9.6 0.85 (0.76-0.96) 2.47 (2.24-2.73)
17 Upper respiratory
disease, other
j
8.9 A, B
P 1441 19.4 650 18.7 791 20.1 1098 14.8 0.95 (0.85-1.07) 1.39 (1.27-1.51)
18 Allergic reactions
k 17.1.9 A 1104 14.9 616 17.8 488 12.4 714 9.6 1.60 (1.41-1.83) 1.64 (1.48-1.81)
19 Genitourinary
symptoms and ill-
defined conditions
l
10.1.8 Unk 1098 14.8 483 13.9 615 15.6 677 9.1 0.89 (0.78-1.01) 1.73 (1.56-1.92)
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1Table 3 25 most prevalent comorbidities and symptoms in the overall HCV population stratified and compared by antiviral treatment status and control
patients without HCV (Continued)
20 Substance-related
mental disorders
5.2.2 E 1091 14.7 443 12.8 648 16.4 818 3.2 1.07 (0.94-1.22 1.39 (1.26-1.53)
21 Blindness and vision
defects
6.7.4 A 1078 14.6 512 14.8 566 14.4 818 11.0 1.07 (0.94-1.22) 1.80 (1.62-2.01)
22 Depressive disorder 5.9.2 A, B, D 1028 13.9 489 14.1 539 13.7 312 4.2 1.06(0.92-1.21) 3.72 (3.25-4.27)
23 Diabetes mellitus
without
complication
3.2 B 1025 13.8 426 12.3 599 15.2 627 8.5 0.74 (0.65-0.85) 1.80 (1.62-2.01)
24 Viral infections,
other
m
1.3.3 Unk 1019 13.8 447 12.9 572 14.5 663 8.9 0.87 (0.76-0.99) 1.63 (1.47-1.81)
25 Eye disorders, other
n 6.7.6 A 1001 13.5 499 14.4 502 12.7 758 10.2 1.23 (1.08-1.41) 1.38 (1.25-1.53)
CCS Clinical Classification Code
*Odds ratios are adjusted for age, sex, and advanced liver disease status
‡ Comorbidities associated with HCV treatment: (A) conditions associated with inteferon alfa or ribavirin use and (B) concurrent disease for which therapy is contraindicated; and HCV disease: (C) symptoms of HCV
disease, (D) extrahepatic manifestations associated with HCV infection, and (E) conditions associated with disease progression; Unk, unknown
a Of the patients who had other liver diseases, they reported abnormal liver function (69.5%), elevated transaminase/lactate dehydrogenase (26.7%), abnormal serum enzyme levels (13.8%), ascites (10.7%), and
hepatomegaly (9.0%)
b Of the patients who had other connective tissue disease, they mainly reported pain in limb (38.7%), myalgia and myositis unspecified (18.8%), swelling of limb (12.5%), and spasm of muscle (9.7%)
c Of the patients who had other and unspecified lower respiratory disease, they mainly reported coughs (48.5%), other respiratory abnormalities (35.6%), shortness of breath (34.1%), and other lung disease
e Of the patients who had other non-traumatic joint disorders, they mainly reported joint pain in the leg (25.5%), shoulder (24.1%), ankle (15.9%), and pelvis (14.4%)
f Of the patients who had other skin disorders, they mainly reported other nonspecified skin eruptions (22.3%), sebaceous cyst (14.3%), actinic keratosis (12.3%), and other seborrheic keratosis (10.8%)
g Of the patients who had other unspecified gastrointestinal disorders, they mainly reported diarrhea (26.7%), splenomegaly (20.3%), irritable bowel syndrome (11.9%), and unspecified site of abdominal/pelvic
swelling (10.6%)
h Of the patients who had other unspecified benign neoplasm, they mainly reported benign neoplasm of the large bowel (39.2%), skin trunk (14.3%), and unspecified skin (11.5%)
i Of the patients who had esophageal disorders, they mainly reported esophageal reflux (62.6%), reflux esophagitis (21.1%), esophagitis unsepcified (14.5%), and esophageal varices without bleeding (13.7%)
j Of the patients who had other upper respiratory disease, they mainly reported unspecified allergic rhinitis (43.0%), rhinitis due to pollen (13.6%), chronic rhinitis (12.4%), nasal cavity/other sinus disorder (12.2%),
epistaxis (11.1%), and deviated nasal septum (11.0%)
k Of the patients who had allergic reactions, they mainly reported unspecified dermatitis (65.9%) and other atopic dermatitis (11.1%)
l Of the patients who had genitourinary symptoms and ill-defined conditions, they mainly reported hematuria (32.0%), urinary frequency (20.1%), and dysuria (18.9%)
m Of the patients who had other viral infections, they mainly reported unspecified viral infections (42.8%), unspecified viral warts (22.0%), and unspecified herpes simplex (11.4%)
n Of the patients who had other eye disorders, they mainly reported unspecified tear film insufficiency (19.7%), other vitreous opacities (15.9%), and vitreous degeneration (9.5%)
o Chronic obstructive pulmonary disease (COPD) may be misclassified under lower respiratory disease which is a antiviral treatment contraindication [14]
p Upper respiratory disease, comprising mainly of rhinitis, may reflect an under-diagnosis of thyorid disorders, which is known to be associated with HCV [15].
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1shown. For a number of conditions where the CCS cate-
gory name is denoted with “other” or was considered
not to be fully explanatory, we described the most com-
mon conditions that were classified within that comor-
bidity by ICD-9 codes as a table footnote. Eight
symptoms (denoted by category C) and eighteen comor-
bid conditions were identified among the top 25 list.
Among the top ranked conditions, the majority of the
comorbidities were grouped into 7 wider body system
classes as follows: diseases of the digestive system (liver
diseases, other [rank 1], gastrointestinal disorders, other
and unspecified [rank 13], esophageal disorders [rank
16]), disease of the musculoskeletal system and connective
tissue (connective tissue disease, other [rank 2], back pro-
blems, other [rank 7], non-traumatic joint disorders,
other [rank 8]), diseases of the respiratory system (upper
respiratory infections, other [rank 4], unspecified lower
respiratory disease, other [rank 5], upper respiratory dis-
ease, other [rank 17]), diseases of the circulatory system
(essential hypertension [rank 6], non-specific chest pain
[rank 10]), endocrine, nutritional and metabolic diseases
and immunity disorders (disorders of lipid metabolism
[rank 11] and diabetes mellitus without complication
[rank 23]), mental disorders (alcohol and substance-
related mental disorders [rank 20] and depressive disor-
ders [rank 22]), and diseases of the nervous systems and
sense organs (blindness and vision defects [rank 21], eye
disorders, other [rank 25]). Symptoms and signs influen-
cing health status (malaise and fatigue [rank 12] and
allergic reactions [rank 18])w e r ea l s oc o m m o ni nt h i s
HCV population.
Other liver diseases (37.5%) was the most common
comorbidity (inclusive of symptoms) identified in this
HCV population, and of these patients, 70% reported
abnormal liver function, 26.7% elevated aminotransami-
nases, 13.8% abnormal serum enzyme levels, 10.7% ascites,
and 9.0% hepatomegaly. In addition, these patients were
more likely to have been treated during the study period
(odds ratio, OR = 1.34, 95% CI: 1.21-1.47).
Comorbidities associated with HCV antiviral treatment
We note that several conditions associated with antiviral
treatment (see Table 3; A) were ranked among the top 25
comorbidities: muscle aches (denoted within connective
tissues disease, 34.6% of those treated), sinusitis (within
upper respiratory infections, 34.7%), skin irritation (within
skin disorders, 28.8% and allergic reactions, which com-
prised mainly unspecified dermatitis, 17.8%), malaise and
fatigue (26.9%), anemia (28.3%), visual disturbances (within
blindness and vision defects, 14.8% and eye disorders,
other, 14.4%) and depressive disorders (14.1%), however,
only those reporting malaise and fatigue (OR = 1.18, 95%
CI: 1.07-1.32), anemia deficiency (OR = 1.99, 95% CI:
1.77-2.23) and eye disorders, other (OR = 1.23, 95% CI:
1.08-1.41) were significantly more likely to be treated dur-
ing the study period. Thyroid disorders, which are contra-
indicated for treatment, did not rank in the top 25
comorbid conditions (prevalence, 12.5%). However, upper
respiratory disease (19.4%; rank 17), was comprised mainly
of rhinintis, which is known to be associated with thyroid
disorders [16]. Therefore, the high prevalence of rhinitis
may suggest the under-diagnosis of thyroid disorders in
this HCV population. There was no difference in treat-
ment status for patients with upper respiratory disease,
although patients with thyroid disorders were more likely
to be treated (OR = 1.60; 95% CI: 1.39-1.85) in our study
population (data not shown).
Several conditions which preclude patients from treat-
ment (see Table 3; B) were also among the top comorbid-
ities; diabetes mellitus without complications (13.8%), and
depressive disorders (13.9%), however only those with dia-
betes mellitus without complications were less likely to be
treated during the study period (OR = 0.74, 95% CI: 0.65-
0.85). Non-specific chest pain (26.5%) could be a symptom
of HCV disease or result as an adverse event from pegy-
lated interferon treatment (mainly Pegasys [17]), and it
was identified in our ranked list of comorbidities.
Although we cannot determine which condition chest
pain is associated with, these patients were less likely to be
treated (OR = 0.84; 95% CI: 0.76-0.94). We did not identify
chronic obstructive pulmonary disease (COPD) in our top
list of comorbidities, an antiviral treatment contraindica-
tion, however, it ranked only slightly lower than our top
25 (prevalence, 13%).
Although disorders of lipid metabolism [rank 11] was
not defined by HCV management guidelines in Table 1,
HCV infection is known to be associated with enhanced
lipogenesis, reduced secretion, and b-oxidation of lipids;
therefore, it was not surprising that it ranked in our most
frequent list of comorbidities [18].
Comorbidites associated with HCV disease
We also found that several conditions associated with
HCV disease ranked among the top 25 comorbidities.
Among the symptoms associated with HCV disease (see
Table 3; C), joint pain (including back problems (32.5%)
and joint disorders (29.3%)) and abdominal pain (36.1%)
were identified; and these patients were less likely to be
treated. In addition, gastrointestinal disorders (24.4%)
comprising mainly of diarrhea, splenomegaly, irritable
bowel syndrome and unspecified site of abdominal/pelvic
swelling may also result in abdominal pain.
Among the common extrahepatic manifestations seen
among chronic HCV patients (see Table 3; D), we identi-
fied rheumatoid symptoms (denoted within connective tis-
sue disease and malaise/fatigue) and psychological
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depressive disorders) to be the most prevalent in our study
population.
Among the comorbidities known to be associated with
liver disease progression (see Table 3; E), substance-
related mental disorders, (associated with drug and alco-
hol use) and essential hypertension ranked in our top
list, and those with substance-related mental disorders
were less likely to be treated (OR = 0.70, 95% CI: 0.61-
0.80). Although HIV, HBV, obesity did not rank in our
list, the prevalence of these comorbidities were 3.2%,
8.4%, and 3.8%, respectively. Approximately 20% of the
HCV population had advanced liver disease (cirrhosis
and HCC); and these patients are at risk of developing
further complications from cirrhosis which occur as a
result of portal hypertension and hyperdynamic circula-
tion [19]. This is evidenced by the high ranking of eso-
phageal disorders (particularly esophageal varices) in our
ranking of most common comorbidities.
Comorbidities not known to be associated with HCV
antiviral treatment or disease
Of the top 25 ranked list of comorbidities, the condi-
tions (n = 3) that were not known to be associated with
antiviral treatment or disease, and hence were least
expected, were benign neoplasms, upper respiratory dis-
ease, genitourinary symptoms and ill-defined conditions,
and viral infections (which was defined mainly by
unspecified viral infections, viral warts, and unspecified
herpes simplex). These conditions were about 1.3- to
1.7-fold higher in the HCV-population compared to the
HCV uninfected controls.
Ranking of top 25 comorbidities according to HCV status
The top ranking comorbidities among the overall HCV
population were consistently identified in the top 25
comorbidities list of stratified groups of HCV treated,
untreated, and controls populations, however with dif-
ferent prevalence and ranking orders (data not shown).
There were a few exceptions. Specifically, diabetes melli-
tus without complication did not rank among the top-
ranked list of comorbidities among HCV treated
patients, whereas patients with thyroid disorders (13.4%;
mainly hypothyroidism) were recorded. Among the
HCV untreated patients, eye disorders and allergic reac-
tions were not seen, whereas cardiac dysrhythmias
(14.0%) and osteoarthritis (13.5%) ranked. Amongst the
uninfected control group, other liver diseases, anemia
deficiency, substance-related mental disorders, and
depressive disorders were not present in the top 25 list,
whereas bone disease and musculoskeletal deformities,
other (9.1%), ear and sense organ disorders, other
(8.8%), non-malignant breast conditions (8.7%), and car-
diac dysrhythmias (8.3%) ranked.
Comorbidities in the HCV population (regardless of
treatment status) were more prevalent than in the con-
trols, except for disorders of lipid metabolism (32.2%
among controls vs. 25.9% among cases; OR = 0.73; 95%
CI: 0.68-0.79). Not surprising, HCV cases with other
liver diseases (OR = 19.67; 95% CI: 16.57-23.36) had the
highest OR compared to the HCV controls, followed by
those with anemia deficiency (OR = 4.57; 95% CI: 4.06-
5.14) and depressive disorder (OR = 3.72; 95% CI: 3.25-
4.27).
Discussion
To our knowledge, this is the first study to systemati-
cally profile non-selected comorbidities in an HCV
population. Nearly every HCV patient in our study had
at least one comorbidity, and in general, these comor-
bidities were more common in the overall HCV infected
case patients compared to the uninfected controls. In
addition, comorbidities covered a wide range of diseases
and symptoms affecting a number of body systems. Our
findings substantiate that HCV is a systemic disease
with many extra-hepatic features which highlight the
urgency to treat these extra-hepatic conditions regard-
less of the liver disease itself. Individualized anti-viral
treatment decisions for HCV infection should weigh the
potential risks and benefits of both hepatic and extra-
hepatic manifestations to increase the likelihood of
treatment success.
Our insured study population reported a 47% current
treatment rate, which is comparable to treatment rates
(10-51%) in other US medical claims database studies
[20-22]. There are multiple reasons why HCV patients
may not be treated which include disease stage, patient
choice and lack of access to liver specialists [23]. Non-
liver specialists may decide that the patient is ineligible
for treatment based on a list of contraindications,
whereas liver specialists may otherwise safely treat the
patient with relative contraindications (i.e. patients with
cirrhosis and moderate thrombocytopenia) since most
treatment regimens are individualized to achieve maxi-
mal sustained virological response. Treatment rates
appear to be declining in the US, and it is estimated
that from 2002-2030, only 14.5% of liver-related deaths
caused by HCV will be prevented [24]; therefore, it is
urgent to understand what barriers may exist that are
preventing treatment uptake as the burden of HCV
morbidity and mortality increases.
Up to one-third of our HCV population had a comor-
bidity that could potentially make them ineligible for
antiviral HCV treatment. This indicates that a high pro-
portion of the HCV population could potentially receive
effective treatment if their comorbid conditions could
be managed. A recent review has reported that the ben-
efits of treatment can potentially reach a wider HCV
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drug users and persons those with psychiatric illnesses
[25]. These patients were able to complete antiviral ther-
apy, achieve a sustained virological response, and did
not develop adverse events that would require disconti-
nuation of treatment. However, it was recommended
that individualized management of these patients could
be integrated within addiction and treatment services
[26]. These studies suggest that some comorbidities can
be effectively managed, increasing access to HCV treat-
ment with successful outcomes.
Our findings confirm previous studies as we consis-
tently observed the known comorbidities associated with
HCV antiviral treatment and disease among our top
ranked list, highlighting that our systematic evaluation
supports how common these conditions are among the
HCV infected population. However, three conditions,
benign neoplasms, genitourinary symptoms, and viral
infections, were identified in our ranked list and have not
been previously reported to be associated with treatment
or disease progression. The prevalence of benign neo-
plasms were mainly of the large bowel and skin (trunk
and unspecified sites), which could possibly be explained
by metastasis to these sites among HCV patients with
HCC but its pathophysiology is unclear and warrants
further study [27,15]. In our study, the prevalence of
HCC was low, but we cannot exclude the possibility that
this may be an underestimation if patients were diag-
nosed prior to the study period. HCV patients with geni-
tourinary symptoms were mainly of hematuria and
proteinuria [28] which could be clinical manifestations of
glomerular kidney disease that is known to be associated
with cryoglobulinemia and membranoproliferative glo-
merulonephritis [29]. For the unexpected finding of viral
infections, the significance is difficult to interpret given
the lack of specificity as almost half the cases were coded
as non-specific viral infections.
Our HCV infected population was more likely to report
comorbidities than the uninfected controls. This may be
explained in part by the higher-risk or unhealthy beha-
vior (e.g., alcohol and drug users) of those infected with
HCV, making them more vulnerable to acquire new mor-
bidities than the uninfected population. Indeed, preva-
lence of alcohol use and drug-use were much higher
among the HCV infected compared to the uninfected
population (alcohol; 7% vs. < 1%; drug use 15% vs. 3%,
respectively). In addition, HCV-infected patients with
health insurance may have closer follow-up care and
higher rates of screening for other diseases than the unin-
fected, hence increasing the reporting of conditions.
HCV-infected patients may also have more comorbidities
because of the illness itself, which may place them at
higher risk for other conditions. However, we identified
disorders of lipid metabolism to be significantly lower
among the HCV population compared to the uninfected
population. This finding is not clearly understood since
HCV infection is associated with enhanced lipogenesis
that may lead to the pathological development of steato-
sis and metabolic syndromes such as insulin resistance,
obesity, and HCC [18].
Our study has several limitations. Firstly, as we used a
medical claims database, we did not have liver histology
data to confirm stage of disease and thus cannot exclude
the possibility of case ascertainment bias as the selection
of cases required at least two clinical ICD-9 HCV diagno-
sis codes for (e.g. patients with more advanced liver dis-
ease or on anti-viral treatment would have more clinical
visits). Secondly, since data were limited on HCV geno-
types (< 1%) and unavailable for racial groups, we were
unable to match on these factors in our analyses although
HCV disease/treatment efficacy is known to vary by geno-
type and race [30]. Thirdly, we relied on clinical coding for
disease stage so the potential for misclassification of HCV
diagnosis and liver disease stage cannot be ruled out. In
addition, we cannot exclude the possibility of inconsistent
coding or misclassification of comorbidities in our study;
for example, COPD, which did not rank in our top 25 list,
could have been misclassified under lower respiratory dis-
ease which ranked 5. Similarly, cutaneous conditions such
as lichen planus and porphyria cutanea tarda which are
commonly seen extrahepatic manifestations did not rank
in the top 25, however, it is possible that these dermatolo-
gic conditions could be misclassified under allergic reac-
tions [rank 18], which was mainly composed of
unspecified dermatitis (65.9% of HCV patients with aller-
gic reactions). Furthermore, given the cross-sectional
design of this study, we were unable to establish the tem-
poral sequence of events, i.e. whether a comorbidity, such
as anemia deficiency, allergic reactions or eye disorders
occurred prior to treatment, during treatment, or were
treatment side effects. Lastly, patients captured in a medi-
cal claims database may be a biased selection of the HCV
population as it does not reflect the population who do
not have access to healthcare, so estimates of these comor-
bidities should be extrapolated with caution to the general
HCV population. However, our results could be general-
ized to the privately insured population. According to
population-based data from the National Health and
Nutrition Examination Survey (NHANES), 61% of those
chronically infected with HCV had health insurance and
among those insured, half of them had private health
insurance [31]. Despite these limitations, our study
includes a much broader HCV population than previous
studies, which were limited to select populations of US
veterans [14,32,33], dialysis patients [34], psychiatric
patients [35] and drug users [36]; and represents an
insured population that would have access to treatment if
comorbidities were able to be managed.
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In summary, this study identified a wide range of highly
prevalent comorbidities, which may have implications
for HCV prognosis, management and treatment success.
With over 4 million Americans currently infected with
HCV, it is one of the most pressing public health chal-
lenges. Effective strategies to manage and control
comorbidities among chronic HCV patients may result
in increased access to treatment, thereby reducing the
future burden of HCV disease and its manifestations.
Additional material
Additional file 1: Appendix A. Excluded comorbidities that reflect acute
conditions, injuries/poisoning, gender-related conditions, and routine/
health maintenance.
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